dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Barrecheguren Fernández, Miriam |
dc.contributor.author | Solntseva, Iryna |
dc.contributor.author | Dhalwani, Nafeesa |
dc.contributor.author | Booth, Alison |
dc.contributor.author | Nuñez Dubon, Alexa Gabriela |
dc.contributor.author | Miravitlles Fernández, Marc |
dc.contributor.author | Monteagudo, Mònica |
dc.date.accessioned | 2021-11-15T09:41:45Z |
dc.date.available | 2021-11-15T09:41:45Z |
dc.date.issued | 2021-03-22 |
dc.identifier.citation | Monteagudo M, Barrecheguren M, Solntseva I, Dhalwani N, Booth A, Nuñez A, et al. Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD. NPJ Prim Care Respir Med. 2021 Mar 22;31:16. |
dc.identifier.issn | 2055-1010 |
dc.identifier.uri | https://hdl.handle.net/11351/6540 |
dc.description | Malaltia pulmonar obstructiva crònica; Epidemiologia |
dc.description.sponsorship | The current study has been funded by an unrestricted grant from AstraZeneca that was also involved in study conception and protocol development. A.N. is the recipient of a Rio Hortega contract in the 2019 Strategic Action Health Call from the Instituto de Salud Carlos III for the years 2020–2022. |
dc.language.iso | eng |
dc.publisher | Nature Research |
dc.relation.ispartofseries | NPJ Primary Care Respiratory Medicine;31 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Malalties obstructives - Tractament |
dc.subject | Pulmons - Malalties obstructives - Diagnòstic |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive |
dc.subject.mesh | /diagnosis |
dc.subject.mesh | Drug Therapy, Combination |
dc.title | Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41533-021-00227-x |
dc.subject.decs | enfermedad pulmonar obstructiva crónica |
dc.subject.decs | /diagnóstico |
dc.subject.decs | farmacoterapia combinada |
dc.relation.publishversion | https://doi.org/10.1038/s41533-021-00227-x |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Monteagudo M] Primary Care University Research Institute Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Barrecheguren M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain. [Solntseva I] Primary Care University Research Institute Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain. [Dhalwani N, Booth A] Evidera, London, UK. [Nuñez A, Miravitlles M] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain |
dc.identifier.pmid | 33753747 |
dc.identifier.wos | 000632053400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |